Results 141 to 150 of about 1,268 (176)
Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series [PDF]
Frontiers in ImmunologyIntroductionAutoimmune encephalitis (AE) comprises a group of inflammatory brain disorders mediated by autoimmune responses. Anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis, anti–leucine-rich glioma-inactivated 1 (LGI1) encephalitis, and anti–γ ...
Qian Yun, Niu Qi
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Efgartigimod in the treatment of Guillain–Barré syndrome
Journal of NeurologyGuillain-Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which thus may be a promising therapeutic drug for GBS.The two patients presented with postinfectious and acute flaccid paralysis.
Huiqiu Zhang +10 more
openaire +2 more sources
Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients [PDF]
Frontiers in NeurologyBackgroundDespite the efficacy of efgartigimod demonstrated in ADAPT phase 3 trial, data specifically derived from Chinese participants are not available.
Ying Tan, Ting Chang, Hui Liang
exaly +3 more sources
Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis [PDF]
Frontiers in ImmunologyIntroductionThis case describes successful response to efgartigimod in the treatment of myasthenic crisis secondary to paraneoplastic disease, and in the perioperative setting.MethodsAn elderly female presented with speech difficulties, cessation of ...
Shahar Shelly
exaly +3 more sources
Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Efgartigimod hilft bei Immunthrombozytopenie
HämostaseologieDie primäre Immunthrombozytopenie (ITP) ist eine erworbene Autoimmunerkrankung durch Autoantikörper gegen thrombozytäre Antigene und gekennzeichnet durch eine isolierte Thrombozytopenie. Efgartigimod bindet den Fc-Rezeptor kompetitiv und bewirkt einen Abbau und die Reduktion zirkulierender IgG-Autoantikörper. In der Phase-3-ADVANCE-IV-Studie
openaire +2 more sources
Efgartigimod: A Review in Generalised Myasthenia Gravis
DrugsEfgartigimod (Vyvgart®; Vyvgart® Hytrulo) is a neonatal fragment crystallizable receptor (FcRn) antagonist indicated for the treatment of generalised myasthenia gravis (gMG) in adults who are acetylcholine receptor (AChR) antibody positive (Ab+). Efgartigimod is approved for both intravenous (IV) and subcutaneous (SC) use. In a pivotal phase III trial,
openaire +2 more sources
Efgartigimod as a novel FcRn inhibitor for autoimmune disease
Neurological SciencesImmunoglobulin G (IgG) autoantibodies can lead to the formation of autoimmune diseases through Fab and/or Fc-mediated interactions with host molecules as well as activated T cells. The neonatal Fc receptor (FcRn) binds at acidic pH IgG and albumin, and the mechanism for prolonging serum IgG half-life is making IgG re-entry into circulation by prompting
Yun Yang +4 more
openaire +2 more sources
Efgartigimod: Potential Impact on IVIG Therapy
The Journal of Allergy and Clinical Immunology: In Practice, 2022Jeffrey G, Demain, Francisco A, Bonilla
openaire +2 more sources
A systematic review of efgartigimod as an effective treatment for myasthenic crisis
Naunyn-Schmiedeberg's Archives of PharmacologyEfgartigimod is a neonatal Fc receptor (FcRn) inhibitor that primarily diminishes antibody levels by inhibiting antibody (IgG) reabsorption and is noted for its rapid onset of action and low immunogenicity. Currently, efgartigimod is approved for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG ...
Ping, Tang +3 more
openaire +2 more sources